Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is a non-infectious, inactivated split-virion monovalent vaccine formulated with the AS03 adjuvant. It is designed to protect against infection caused by the H5N1 subtype of the influenza A virus. The antigen component is produced from H5N1 virus propagated in embryonated hen’s eggs and then inactivated using ultraviolet light. The AS03 adjuvant enhances immune response to the antigen. This vaccine stimulates production of antibodies against H5N1 and is intended for use as part of pandemic preparedness or outbreak response[6][8]. It has been stockpiled by governments for rapid deployment during outbreaks and was developed primarily for protection against avian-origin pandemic strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.